Kintara Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaborations
    • Advisors
  • Pipeline
    • Overview
    • VAL-083
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Recent News
    • Events
  • Investors
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Press Releases

News & Media

News & Media

  • Press Releases
  • Publications and Abstracts
  • Presentations
  • Recent News
  • Events

Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

Dec 15, 2022

Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

Dec 1, 2022

Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nov 30, 2022

Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer

Nov 28, 2022

Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting

Nov 18, 2022

Kintara Announces One-for-Fifty Reverse Stock Split

Nov 11, 2022

Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update

Nov 9, 2022

Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study

Oct 19, 2022

Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update

Sep 27, 2022

Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting

Sep 8, 2022
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...34
    © 2023 Kintara Therapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Legal Information Manage Cookie Preferences